Strategic Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Strategic Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-343	Closed	-$218K	–	246
2025 Q1	$218K	Sell	343 -42	-11%	-$28.9K	0.02%	231
2024 Q4	$275K	Buy	385 +31	+9%	+$26K	0.03%	214
2024 Q3	$373K	Sell	354 -3	-0.8%	-$3.34K	0.04%	203
2024 Q2	$376K	Sell	357 -29	-8%	-$28.1K	0.05%	195
2024 Q1	$372K	Buy	386 +21	+6%	+$20K	0.05%	195
2023 Q4	$321K	Buy	365 +1	+0.3%	+$823	0.05%	198
2023 Q3	$300K	Buy	364 +9	+3%	+$7.07K	0.05%	201
2023 Q2	$255K	Buy	355 +36	+11%	+$27.8K	0.04%	175
2023 Q1	$262K	Buy	+319	New	+$241K	0.05%	214
2020 Q3	–	Sell	-398	Closed	-$248K	–	185
2020 Q2	$248K	Buy	+398	New	+$226K	0.09%	153

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Strategic Investment Advisors's REGN Position: Q2 2025 in Review

Strategic Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 343 shares — an estimated $218K sold.

Strategic Investment Advisors first reported a position in REGN in Q2 2020 and held it in 10 quarters. The position peaked at $376K in Q2 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Strategic Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Strategic Investment Advisors sold 343 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $218K.
Strategic Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 10 quarters.
Strategic Investment Advisors's Regeneron Pharmaceuticals position peaked at $376K in Q2 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Strategic Investment Advisors's 13F filing for Q2 2025, filed 15 Aug 2025.